The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation

Raltegravir (MK-0518) is the first integrase (IN) inhibitor to be approved by the US FDA and is currently used in clinical treatment of viruses resistant to other antiretroviral compounds. Virological failure of Raltegravir treatment is associated with mutations in the IN gene following two main dis...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Delelis, Olivier, Malet, Isabelle, Na, Li, Tchertanov, Luba, Calvez, Vincent, Marcelin, Anne-Genevieve, Subra, Frederic, Deprez, Eric, Mouscadet, Jean-François
פורמט: Artigo
שפה:Inglês
יצא לאור: Oxford University Press 2009
נושאים:
Nucleic Acid Enzymes
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC2651800/
https://ncbi.nlm.nih.gov/pubmed/19129221
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/nar/gkn1050
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים